Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
2 hedge funds and large institutions have $118K invested in Sonnet BioTherapeutics in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
18% more capital invested
Capital invested by funds: $100K → $118K (+$17.8K)
0% more funds holding
Funds holding: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Suntrust Banks
Atlanta,
Georgia
|
+$45.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$19K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$214 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Renaissance Technologies
New York
| $49K | – | – | – |
|
|
SB
2
Suntrust Banks
Atlanta,
Georgia
| $27K | +$45.8K | +1 | New |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $14K | – | – | – |
|
4
Jane Street
New York
| $11K | – | – | – |
|
5
BlackRock
New York
| $8K | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $4K | – | – | – |
|
|
QCIG
7
Quad-Cities Investment Group
Davenport,
Iowa
| $4K | – | – | – |
|
8
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
AFM
9
Anson Funds Management
Dallas,
Texas
| – | -$214 | -3 | Closed |
|
|
10
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$19K | – | – |
|
SONN Hedge Fund Activity: Q3 2019 in Review
2 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2019, worth a combined $118K — up 18% from $100K a quarter earlier.
Fund positioning in SONN was balanced in Q3 2019: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Suntrust Banks, opening a new position worth an estimated $45.8K. The largest seller was Hudson Bay Capital Management, cutting an estimated $19K.
- 2 institutional investors held Sonnet BioTherapeutics (SONN) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $118K of Sonnet BioTherapeutics stock for Q3 2019, up 18% quarter-over-quarter.
- 1 fund opened new Sonnet BioTherapeutics positions in Q3 2019 and 1 closed out, a net change of 0 holders.
- The largest Sonnet BioTherapeutics buyer in Q3 2019 was Suntrust Banks, an estimated $45.8K added.
- The largest Sonnet BioTherapeutics seller in Q3 2019 was Hudson Bay Capital Management, an estimated $19K sold.
Based on aggregated 13F filings for Q3 2019.